Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration...
Chipscreen Biosciences
Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...
Chipscreen’s Epidaza Patent Faces Invalidation Request Review
China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for CS231295 Solid Tumor Study
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced receiving the...
Chipscreen Biosciences’ Chiauranib Phase III Trial Results for SCLC Announced
China-based innovative drug company Chipscreen Biosciences (SHA: 688321) has announced the completion of the analysis...
Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a...
Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the...
Shenzhen Chipscreen Biosciences’ Tivozanib Secures NMPA Approval for ES-SCLC Phase III Trial
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has announced that the National Medical Products Administration...
Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch
China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical...
Shenzhen Chipscreen Advances CS231295 for Cancer Treatment as IND Accepted by NMPA
On October 17, Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that its innovative Class...
Chipscreen’s HDAC Inhibitor Chidamide to be Tested in Combination Therapy for CRC by NMPA
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has received...
NMPA Approves Chengdu Chipscreen’s Bilessglu for Type 2 Diabetes in Combination with Metformin
The National Medical Products Administration (NMPA) has granted approval for Shenzhen Chipscreen Biosciences Co., Ltd...
Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Phase II Trial in Pancreatic Cancer
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...
Chipscreen’s Chidamide in Sight of Breakthrough Therapy Designation in China for MSS/pMMR Colorectal Cancer
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...
China’s NMPA Approves Shenzhen Chipscreen’s Chidamide for DLBCL Indication
Shenzhen Chipscreen Biosciences Co., Ltd, a biopharmaceutical company based in China, announced that it has...
Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001
China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for Phase I Study of CS32582 in Psoriasis
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced that it...
CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China
US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with...
Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan
Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...